BioNTech Halts Phase II Autogene Cevumeran Trial in Colorectal Cancer
BioNTech terminated the Phase II BNT122-01 trial of its individualized neoantigen mRNA cancer vaccine autogene cevumeran in colorectal cancer after an independent data safety monitoring board identified a numerical overall survival imbalance, following the…
